- D(-)-Arginine
-
- $999.00
-
2026-09-23
- CAS:157-06-2
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 5000
- D(-)-Arginine
-
- $100.00
-
2026-09-23
- CAS:157-06-2
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 5000
- D(-)-Arginine
-
-
2026-09-23
- CAS:157-06-2
- Min. Order: 1kg
- Purity: 98%min
- Supply Ability: 500kg
|
| | D(-)-Arginine Basic information |
| | D(-)-Arginine Chemical Properties |
| Melting point | 226 °C (dec.) (lit.) | | alpha | -28.5 º (c=8, 6 N HCl) | | Boiling point | 305.18°C (rough estimate) | | density | 1.2297 (rough estimate) | | refractive index | -23 ° (C=8, 6mol/L HCl) | | storage temp. | Keep in dark place,Inert atmosphere,Room temperature | | solubility | Aqueous Acid (Slightly), Water (Slightly) | | form | Solid | | pka | 2.49±0.24(Predicted) | | color | White to Off-White | | Water Solubility | SOLUBLE | | Specific Heat Capacity | Cp(crystal): 1.33 J/(g·K), at 25℃ | | Sensitive | Air Sensitive | | BRN | 1725412 | | Major Application | peptide synthesis | | InChI | 1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m1/s1 | | InChIKey | ODKSFYDXXFIFQN-SCSAIBSYSA-N | | SMILES | N[C@H](CCCNC(N)=N)C(O)=O | | LogP | -0.999 (est) | | CAS DataBase Reference | 157-06-2(CAS DataBase Reference) | | EPA Substance Registry System | D-Arginine (157-06-2) |
| Hazard Codes | Xi,Xn | | Risk Statements | 36-36/37/38-20/21/22 | | Safety Statements | 26-36 | | WGK Germany | 3 | | RTECS | CF1934220 | | F | 9 | | TSCA | TSCA listed | | HazardClass | IRRITANT | | HS Code | 29252000 | | Storage Class | 11 - Combustible Solids |
| | D(-)-Arginine Usage And Synthesis |
| Description | D-arginine is the D-form of arginine, which is a kind of amino acids. It can be reacted with hydrogen peroxide for non-enzymatic synthesis of nitric oxide. It has certain pharmacological activities. For example, its derivative, 1-deamino-8-D-arginine vasopressin is useful for the management of haemophilia and von Willebrand’s disease. It also has the potential to inhibit the proliferation of certain cancer cells. In biological research, D-arginine is frequently used in the studies of L-arginine/nitric oxide pathway as an inactive form of L-arginine. | | Chemical Properties | white to light yellow crystal powde | | Uses | Arginine is an essential amino acid found in food and plant sources, and many biological systems.
D-Arginine is extensively used in studies on L-arginine/nitric oxide pathway as an inactive form of L-arginine, even in man.
D-Arginine is slightly soluble (in water) and a moderately acidic compound (based on its pKa). D-Arginine can be found in human epidermis and platelet tissues. Within the cell, D-arginine is primarily located in the peroxisome. D-Arginine specifically can inhibit arginine decarboxylase enzymes and also functions as a metabolite. | | Uses | 1-Deamino-8-D-arginine vasopressin makes a new pharmacological approach to the management of haemophilia and von Willebrand's disease. A novel nonenzymatic pathway for the generation of nitric oxide is by the reaction of hydrogen peroxide and d- or l-arginine. | | Definition | ChEBI: D-arginine is a D-alpha-amino acid that is the D-isomer of arginine. It has a role as an EC 4.1.1.19 (arginine decarboxylase) inhibitor and a mouse metabolite. It is a D-alpha-amino acid and an arginine. It is a conjugate base of a D-argininium(1+). It is a conjugate acid of a D-argininate. It is an enantiomer of a L-arginine. | | in vivo | D-arginine (1 mg/kg, i.v., caudal veins, every two days) sensitize osteosarcoma to radiotherapy in a mouse model of subcutaneous osteosarcoma[3].
The number of D-arginine residues in cell-penetrating peptides (i.v.) significantly affects their cellular uptake behavior and systemic toxicity in mice[4].
D-Arginine (700 mg/kg, i.p.) displays central stimulant properties and increases spontaneous motor activity in mice[5].
D-arginine (i.p.) shows a light toxicity order (LD50: 2800 mg/kg) in mice[5].
D-arginine (1400 mg/kg, i.p.) protects against Pentylenetetrazole-induced convulsions in mice[5].
D-arginine (1000 mg/kg, p.o., 16 weeks) significantly alters various enzymes and metabolites in the arginine metabolic pathways in male SD rats[6].
D-arginine (1000 mg/kg, s.c., coadministered with L-arginine) blocks antinociception elicited by L-arginine (HY-N0455) in mice with Carrageenin-induced hyperalgesia[7].
D-arginine (20 mg/kg, s.c.) does not significantly alter the percentage of antinociception in mice[8].
| Animal Model: | Female BALB/c mice (anesthetized by intraperitoneal injection of 3% pentobarbital sodium; K7M2 cells were injected subcutaneously; X-ray irradiation)[2] | | Dosage: | 1 mg/kg | | Administration: | Intravenous injection (i.v.), caudal veins, every two days | | Result: | Inhibited tumor volume (20 days).
|
| | IC 50 | Human Endogenous Metabolite | | References | https://www.alfa.com/zh-cn/catalog/A16137/
Iannucci, N. B., et al. "Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells." Future Medicinal Chemistry 3.16(2011):1987-1993.
Ripoll, Giselle, et al. "Angiostatic activity of 1-Deamino-8-D-Arginine vasopressin and novel peptide analogues in breast cancer cells." Cancer Research 68(2008).
Navarro, Eduardo, et al. "Toxicological and Pharmacological Effects of D-Arginine." Basic & Clinical Pharmacology & Toxicology97.3(2005):149-154. |
| | D(-)-Arginine Preparation Products And Raw materials |
|